As a scorching summer kicks off, we're pleased to welcome four research groups from SUPSI, who joined Biotechnet as an affiliated member this year. We look forward to getting to know their expertise and involving them in our thematic platforms.
To create synergies between our organisations in infectious disease prevention and treatment, we signed a collaboration agreement with the Swiss Biorisk Alliance.
Finally, we warmly welcome early-career scientists as part of Biotechnet's Young Reps committee.
We wish you restful time off with family and friends and look forward to seeing you at our events this fall!
News
Ticino - a wealth of expertise at new member groups from SUPSI Department of Innovative Technologies
As a national association that brings together UAS and other applied research organisations, we're very happy to expand our coverage of biotech expertise in Ticino! We warmly welcome the following groups from affilated member SUSPI. Please reach out to these groups if you're interested in learning more about their activities or collaborating with them.
Laboratory of Computational Materials Science
Group leader: Charly Empereur-Mot
Our expertise ranges from molecular modeling in biology to materials modeling in energy applicataions.
In biotech and medical research, we focus on protein design (peptides, nanobodies, antibodies), small molecule selectivity and oncology applications.
We work closely with industry partners to develop practical solutions across the full life cycle of production systems. Our areas of focus are software-defined industrial operations, sustainable and circular manufacturing, and human-centred smart production.
We develop innovative technologies at the intersection of engineering, biology, and medicine. Our focus areas are advanced organ-on-chip and microfluidics, miniaturized diagnostic technologies for precision medicine, and digital biomarkers for quantitative human movement analysis.
Artificial intelligence in health and life sciences
Group leader: Laura Azzimonti
We conduct research at the intersection of AI and biomedical science. Our focus areas are personalised and predictive medicine, natural language processing for health care, computer vision and biomedical imaging, and computational biology for protein understanding and drug design.
Early-career scientists can play an important role in actively shaping our network. To this end, Biotechnet's full and affiliated members are forming a young representatives committee!
We're excited to welcome the following scientists as Biotechnet young reps:
Dr.Ing. Jan Ott, ZHAW Institute of Chemistry and Biotechnology
Prof. Dr. Laura Rolinger, HES-SO Valais Institute of Life Sciences
Jennifer Nika, SUPSI Department of Innovative Technologies
Prof. Dr. Maëlle Bochud, HEIA-FR ChemTech and Biofactory Competence Centre
Marcel Suleiman, FHNW Institute for Chemistry and Bioanalytics
Dr. Julija Pecerska, ZHAW Institute of Computational Life Sciences
Some young reps will participate in the Biotechnet summer school in Sion this September. The committee's official kick off meeting will take place in the fall and we're looking forward to hearing about their first ideas and activities!
Collaboration partnership with the Swiss Biorisk Alliance
Biotechnet is pleased to announce a collaboration partnership with the Swiss Biorisk Alliance. The two associations agree to exchange information about events and initiatives, and provide each other access to expertise in our networks.
This partnership is relevant to two of Biotechnet's thematic platforms interested in infectious diseases: the Antibiotics plaform and the In Vitro Diagnotics platform. Moreover, manufacturing of vaccines and emergency medicines is relevant to our Biomanufacturing platform.
We look forward to connections between our experts and invite you to mark your calendars for the Swiss Biorisk Alliance's annual meeting on November 20, 2026 in the afternoon.
As part of the Eureka initiative, Swiss companies and research institutes are invited to undertake R&D projects focused on biotech at an international level.
